It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Rs3814113 is the single-nucleotide polymorphism (SNP) showing the strongest association with high-grade serous ovarian carcinoma (HGSOC) incidence and is located in an intergenic region about 44 kb downstream of basonuclin 2 (BNC2) gene. Lifetime number of ovulations is associated with increased risk to develop HGSOC, probably because of cell damage of extrauterine Müllerian epithelium by ovulation-induced oxidative stress. However, the impact of low-penetrance HGSOC risk alleles (e.g. rs3814113) on the damage induced by oxidative stress remains unclear. Therefore, the purpose of this study was to investigate whether rs3814113 genetic interval regulates BNC2 expression and whether BNC2 expression levels impact on cell survival after oxidative stress. To do this, we analyzed gene expression levels of BNC2 first in HGSOC data sets and then in an isogenic cell line that we engineered to carry a 5 kb deletion around rs3814113. Finally, we silenced BNC2 and measured surviving cells after hydrogen peroxide (H2O2) treatment to simulate oxidative stress after ovulation. In this paper, we describe that BNC2 expression levels are reduced in HGSOC samples compared with control samples, and that BNC2 expression levels decrease following oxidative stress and ovulation in vitro and in vivo, respectively. Moreover, deletion of 5 kb surrounding rs3814113 decreases BNC2 expression levels in an isogenic cell line, and silencing of BNC2 expression levels increases cell survival after H2O2 treatment. Altogether, our findings suggest that the intergenic region located around rs3814113 regulates BNC2 expression, which in turn affects cell survival after oxidative stress response. Indeed, HGSOC samples present lower BNC2 expression levels that probably, in the initial phases of oncogenic transformation, conferred resistance to oxidative stress and ultimately reduced the clearance of cells with oxidative-induced damages.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Centro di Riferimento Oncologico (CRO Aviano), National Cancer Institute, Division of Experimental Oncology2, Department of Translational Research, Aviano, Italy (GRID:grid.418321.d) (ISNI:0000 0004 1757 9741)
2 Centro di Riferimento Oncologico (CRO Aviano), National Cancer Institute, Division of Experimental Oncology2, Department of Translational Research, Aviano, Italy (GRID:grid.418321.d) (ISNI:0000 0004 1757 9741); University of Verona, Department of Life and Reproduction Sciences, Verona, Italy (GRID:grid.5611.3) (ISNI:0000 0004 1763 1124)
3 National Cancer Institute, Division of Experimental and Clinical Pharmacology, Department of Translational Research Centro di Riferimento Oncologico (CRO Aviano), Aviano, Italy (GRID:grid.417893.0) (ISNI:0000 0001 0807 2568)
4 University Hospital of Udine, Department of Oncology, Udine, Italy (GRID:grid.411492.b)
5 University Hospital of Udine, Department of Oncology, Udine, Italy (GRID:grid.411492.b); University of Udine, Department of Medical and Biological Sciences, Udine, Italy (GRID:grid.5390.f) (ISNI:0000 0001 2113 062X)
6 CRO Aviano National Cancer Institute, Division of Pathology, Department of Translational Research, Aviano, Italy (GRID:grid.418321.d) (ISNI:0000 0004 1757 9741)
7 Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico (CRO Aviano), National Cancer Institute, Aviano, Italy (GRID:grid.418321.d) (ISNI:0000 0004 1757 9741)
8 University of Trieste, Department of Life Sciences, Trieste, Italy (GRID:grid.5133.4) (ISNI:0000 0001 1941 4308)